FDA advisory committee to review Evenity (romosozumab) for the treatment of osteoporosis in postmenopausal women at high risk for fracture


The US Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) are to review data supporting the Biologics License Application (BLA) for Evenity (romosozumab) (Amgen and UCB) for the treatment of osteoporosis in postmenopausal women at high risk for fracture at a meeting on 15 January, 2019.

“After a fracture, postmenopausal women with osteoporosis are five times more likely to fracture in the subsequent year, and these fractures can be life-changing. Yet these patients often remain undiagnosed and untreated and could benefit from a potential new bone forming therapy that has been shown to reduce their risk of fracture within the first year,” said David M. Reese, executive vice president of research and development at Amgen. “We look forward to discussing the efficacy and safety data from our Evenity clinical programme with the members of the Committee.”

The Evenity development programme includes three pivotal Phase 3 studies that included more than 11,000 patients: FRAME, including 7,180 postmenopausal women with osteoporosis; ARCH, including 4,093 postmenopausal women with osteoporosis at high risk for fracture; and BRIDGE, including 245 men with osteoporosis. The BRUDAC will focus its discussion on the FRAME and ARCH studies in its review of the clinical benefit:risk profile of Evenity, including the cardiovascular safety findings seen in the ARCH study, for the potential to reduce the risk of fractures and increase bone mineral density (BMD) in postmenopausal women with osteoporosis.

“We are currently seeing a large gap in the management and treatment of osteoporosis, especially in the post-fracture setting, with an estimated 77 percent of women aged 67 or older remaining undiagnosed and untreated in the first six months after a fracture. This is a stark reminder of the need to improve post-fracture care and reduce the risk of future fractures,” said Pascale Richetta, head of bone and executive vice president, UCB.

In July 2018, Amgen and UCB resubmitted the BLA to the FDA for Evenity. Marketing authorisation applications for Evenity are also ongoing in other parts of the world including Europe and Japan.


Please enter your comment!
Please enter your name here